Osimertinib-associated ashy dermatosis–like hyperpigmentation

Lertpichitkul, Pattamon; Wititsuwannakul, Jade; Asawanonda, Pravit; Rerknimitr, Pawinee

doi:10.1016/j.jdcr.2019.11.008

Cited by 11 publications

(19 citation statements)

References 10 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patient experienced pigmentary changes 2 months after starting ribociclib treatment. This is compatible with the reported latency period for drug-induced EDP/AD [ 10 ]. Letrozole-induced EDP/AD was excluded because the cutaneous manifestations started to clear after ribociclib was discontinued and also because skin-related adverse events associated with aromatase inhibitors are uncommon.…”

Section: Discussionsupporting

confidence: 92%

“…Pigmentation that is identical to the morphology of EDP/AD has been reported to occur due to drugs such as proton pump inhibitors, ethambutol, fluoxetine, and chlorothalonil [ 8 ]. AD-like hyperpigmentation that developed 6 months after starting treatment with the drug, has been recently described as being associated with the epidermal growth factor receptor inhibitor osimertinib [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)–Like Pigmentation in a Metastatic Breast Cancer Patient

et al. 2021

View full text Add to dashboard Cite

Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved in combination with endocrine therapy for the treatment of hormone receptor-positive/ human epidermal growth factor 2-negative advanced or metastatic breast cancer. The main dermatological adverse events associated with CDK 4/6 inhibitors that are described in the literature include skin rash, an increased risk of alopecia, and stomatitis. Erythema dyschromicum perstans (EDP), also known as ashy dermatosis, is characterized by acquired small and large slate-gray hyperpigmented macules with erythematous borders. There are currently no published reports of EDP-like or pigmentary changes induced by CDK 4/6 inhibitors. This report describes the first case of EDP-like pigmentation associated with ribociclib therapy.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)–Like Pigmentation in a Metastatic Breast Cancer Patient

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pigmentary lesions gradually developed 8 months after the onset of gefitinib administration. The time interval is compatible with the average time of onset of drug-induced hyperpigmentation, that is 6.5 Dermatology Online Journal || Case Presentation months [3,4]. The other current systemic drugs were used irregularly for a much longer time and despite stopping these drugs, there was further development of hyperpigmentation.…”

Section: Introductionmentioning

confidence: 60%

“…However, hyperpigmentation is rarely reported [2]. We recently reported a case of ashy dermatosis (AD)-like hyperpigmentation induced by osimertinib, a selective inhibitor against EGFR with the T790M mutation [3]. Interestingly, besides cutaneous involvement, hyperpigmentation of the hair and eyebrows in a patient 7 months into gefitinib treatment has also been described [4].…”

Section: Introductionmentioning

confidence: 98%

Gefitinib-associated lichen planus pigmentosus-like eruption

Chuenwipasakul¹,

Wititsuwannakul²,

Asawanonda³

et al. 2021

DOJ

Self Cite

View full text Add to dashboard Cite

“…Several other drugs have also been associated with an ashy dermatosis-like reaction. 9 , 10 Although the exact mechanism and etiology of ashy dermatosis is unknown, the presence of pigmentary incontinence, dermal melanophages, and CD8 + T lymphocytes 2 , 4 suggests that drug-induced antigen sensitization plays an important role.…”

Section: Discussionmentioning

confidence: 99%